Colorectal cancer

Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery

Retrieved on: 
Sunday, January 28, 2024

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024).
  • The data demonstrate that VGT-309, the company’s investigational tumor-targeted fluorescent imaging agent, visualizes primary and metastatic tumor tissue in the lung during surgery.
  • The findings reinforce results from earlier clinical trials of VGT-309 which suggest the agent may help surgeons see difficult-to-find and previously undetected tumors in real time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted lung cancer surgery.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Leal Health Partners with the American Cancer Society to Host "Hope in the New Year" Webinar

Retrieved on: 
Monday, January 29, 2024

Emphasizing the pivotal role of patient empowerment, Tim highlighted the invaluable support offered by patient-centric organizations like Leal Health and the American Cancer Society.

Key Points: 
  • Emphasizing the pivotal role of patient empowerment, Tim highlighted the invaluable support offered by patient-centric organizations like Leal Health and the American Cancer Society.
  • The conversation also spotlighted the American Cancer Society's Hope Lodge program, an initiative that provides free lodging and support to cancer patients and their caregivers during treatment.
  • Together - with the American Cancer Society - we look forward to continuing to make strides against cancer and helping more patients in need."
  • "Our American Cancer Society Hope Lodges create a sense of community for cancer patients and their caregivers," said Chloe Lipman, Vice President of Community Development for the American Cancer Society.

InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China

Retrieved on: 
Wednesday, January 24, 2024

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TRKA with resistant mutations G595R or G667C.

Key Points: 
  • Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant TRKA with resistant mutations G595R or G667C.
  • InnoCare has been advancing the registrational trial of zurletrectinib in China and is expecting to submit the new drug application in the second half of 2024.
  • Dr. Jasmine, the Co-founder, Chairwoman, and CEO of InnoCare, said, “NTRK gene fusion is a driving factor for various adult and pediatric cancers.
  • It is inspiring that we continue to make positive progress in our clinical research of zurletrectinib for patients of different ages with NTRK gene fusion.

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Retrieved on: 
Monday, January 22, 2024

Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, presented these findings at the ASCO-GI conference.

Key Points: 
  • Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, presented these findings at the ASCO-GI conference.
  • "BOT/BAL's potential impact on colorectal cancer is groundbreaking.
  • BOT/BAL Eliminates Circulating Tumor DNA (ctDNA): patients in the NICHE-1 study were tested for ctDNA, a biomarker closely associated with long-term Disease-Free Survival (DFS).
  • Neoadjuvant BOT/BAL in both MSS and MSI-H CRC resulted in marked tumor regression and robust immune cell infiltration in a very short interval.

PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project

Retrieved on: 
Wednesday, January 17, 2024

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

Key Points: 
  • PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancer, announces today the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.
  • Members of the project consortium will receive €8.1M ($8.9M) in funding, including €4.7M ($5.1M) for PDC*line Pharma.
  • View the full release here: https://www.businesswire.com/news/home/20240117630349/en/
    The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
  • Globally, colorectal cancer (CRC) is among the most prevalent and deadly cancers , with a high recurrence rate post-surgery and chemotherapy.

Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence

Retrieved on: 
Wednesday, January 17, 2024

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium, January 18-20 in San Francisco.
  • Guardant Reveal analyzes comprehensive molecular signals in the blood to detect and quantify minimal residual disease (MRD).
  • The COSMOS study evaluated the use of the newest version of the test, built on the Guardant Infinity™ smart liquid biopsy platform, to identify MRD and predict disease recurrence in 130 patients with early-stage (II and III) colon cancer.
  • “Studies have established the presence of residual disease after surgery is associated with a higher probability of recurrence in early-stage colon cancer,” said Craig Eagle, M.D., Guardant Health chief medical officer.

City of Hope Predicts 8 Important Cancer Trends in 2024

Retrieved on: 
Wednesday, January 17, 2024

City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.

Key Points: 
  • City of Hope is leveraging its geography as a national cancer research and treatment system and its diverse patient population to study a number of cancer disparities, including triple-negative breast cancer in African American women, lung cancer in the Asian population and colorectal cancer in the Hispanic population.
  • “City of Hope will soon launch a comprehensive research study validating a blood test developed by researchers at City of Hope and TGen to detect cancers early.
  • Early detection is the key to curing cancer for many,” said Annette Walker, president of City of Hope Orange County.
  • “This is a primary reason City of Hope expanded its National Cancer Institute-designated expertise to Chicago, Phoenix and Atlanta.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.
  • This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

Retrieved on: 
Wednesday, January 24, 2024

CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.

Key Points: 
  • CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements, Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit in Berlin, Germany.
  • Renowned for her pivotal role in mRNA research, Dr. Xiangrong Song, co-founder and CEO of WestGene, presented the latest advances in the company's oncology sector, with a special focus on mRNA-based cancer vaccines.
  • The Summit, held January 23-25, is a key event in the field of mRNA drug development, attracting over 200 specialists from various parts of the world.
  • Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics.

FDA Grants Breakthrough Device Designation to Amadix´s preventive screening blood test for Colorectal Cancer

Retrieved on: 
Tuesday, January 23, 2024

Amadix becomes the first European company to announce this recognition for early detection of colorectal cancer.

Key Points: 
  • Amadix becomes the first European company to announce this recognition for early detection of colorectal cancer.
  • MADRID, Jan. 23, 2024 /PRNewswire/ -- Amadix , a Spanish biotech company, announced today that PreveCol®, its colorectal cancer screening blood test, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
  • With this milestone, Amadix becomes the first European company to announce this recognition for early detection of colorectal cancer.
  • We will continue preventing the onset of colorectal cancer and the complications derived from the current treatments.